MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • MDS Virtual Congress 2020

    Levodopa induced changes of tongue body movements during speech production

    T. Thies, D. Mücke, R. Dano, M.. Barbe (Cologne, Germany)

    Objective: This study investigates the influence of levodopa (L-dopa) on tongue body movements during speaking. Background: Parkinson’s disease (PD) is a neurodegenerative disorder affecting non-motor…
  • 2019 International Congress

    Impulse control and repetitive behavior disorders are more common in PD patients with levodopa-induced dyskinesias

    F. Paolini Paoletti, N. Tambasco, G. Cappelletti, P. Eusebi, S. Simoni, P. Nigro, E. Brahimi, M. Filidei, P. Calabresi (Perugia, Italy)

    Objective: Our aim was to evaluate the prevalence of impulse control and repetitive behavior disorders (ICRB) in patients affected by Parkinson's disease (PD) with and without levodopa-induced…
  • 2019 International Congress

    Evaluating the real-world effectiveness of carbidopa/levodopa enteral suspension (CLES) on patients with advanced Parkinson’s disease in USA: Interim-evidence from the PROviDE study

    R. Pahwa, S. Isaacson, P. Kandukuri, Y. Jalundhwala, P. Kukreja, Y. Bao, N. Gupta, I. Pan, J. Aldred (Kansas City, KS, USA)

    Objective: To evaluate the real-world effectiveness of carbidopa/levodopa enteral suspension (CLES) in patients with advanced Parkinson’s disease (PD) in real world at home setting in…
  • 2019 International Congress

    Changes in close relationships among patients with Parkinson’s disease and their partners following initiation of device-aided treatment

    J. Timpka, M. Scharfenort, T. Sahlström, V. Hernström, T. Henriksen, D. Nyholm, P. Odin (Lund, Sweden)

    Objective: Our primary objective was to study whether there is a difference in how close relationships are perceived by Parkinson’s disease (PD) patients with device-aided…
  • 2019 International Congress

    Patients Experiencing Motor Fluctuations With Parkinson’s Disease (PD): Participant Characteristics in the Accordance Phase 3 Efficacy and Safety Trial of Accordion Pill™ Carbidopa/Levodopa

    P. Lewitt, R. Gendreau, J. Meckler, A. Hotovely-Salomon, N. Navon (West Bloomfield, MI, USA)

    Objective: To provide baseline and clinical characteristics for participants in the phase 3 Accordance study of the Accordion Pill™ (AP)—a gastric-retentive formulation of carbidopa/levodopa (CD/LD)—versus…
  • 2019 International Congress

    Toning down SPNs to improve motor responses to dopaminergic stimulation in Parkinson’s disease

    G. Beck, H. Mochizuki, S. Papa (Atlanta, GA, USA)

    Objective: This study was aimed at examining whether decreasing the baseline SPN firing frequency towards the low activity found in normal conditions reduces LID. Background:…
  • 2019 International Congress

    Are there associations between altered brain connectivity and dopaminergic medication in Parkinson’s disease patients with freezing of gait?

    A. Potvin-Desrochers, A. Atri, C. Paquette (Montreal, QC, Canada)

    Objective: The purpose of this study is to assess how brain connectivity is altered in Parkinson’s disease (PD) patients with freezing of gait (FOG), and…
  • 2019 International Congress

    Long-term impact of Levodopa Carbidopa Intestinal Gel (LCIG) on reducing “Off” time: Results from a systematic review of studies with ≥ 12 months of follow-up

    A. Antonini, P. Odin, R. Pahwa, J. Aldred, A. Alobaidi, Y. Jalundhwala, P. Kukreja, L. Bergmann, S. Inguva, Y. Bao, K. Chaudhuri (North Chicago, IL, USA)

    Objective: The objective of this study was to summarize evidence evaluating long-term (i.e. ≥ 12 months)efficacy of levodopa carbidopa intestinal gel (LCIG) on “off” time,…
  • 2019 International Congress

    Evaluating the real-world impact of levodopa/carbidopa intestinal gel (LCIG) on motor symptoms using wearable sensors: Evidence from PROviDE study

    R. Pahwa, R. Dorsey, S. Isaacson, P. Kandukuri, Y. Jalundhwala, P. Kukreja, N. Gupta, I. Pan, Y. Bao, D. Heldman (Kansas City, KS, USA)

    Objective: To objectively evaluate the real-world impact of carbidopa/levodopa enteral suspension (CLES) on motor symptoms in patients with advanced Parkinson’s disease (PD) in USA. Background:…
  • 2019 International Congress

    Stigma and Quality of life in Parkinson’s disease patients on different treatment regimens

    O. Vanta, L. Perju-Dumbrava, L. Perju-Dumbrava (Cluj-Napoca, Romania)

    Objective: To assess self reported quality of life (QOL) in patients with Parkinson’s disease (PD) under different treatment options and to evaluate the emotional burden…
  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley